

innovations

from The University of Vermont

TITLE: USE OF INHIBITORS OF PACAP RECEPTOR ACTIVITY FOR TREATMENT OF OVERACTIVE BLADDER AND PELVIC FLOOR PAIN SYNDROME

INVENTORS: Margaret Vizzard, Peter Zvara

DESCRIPTION: Pituitary adenylate cyclase-activating polypeptide (PACAP) is a polypeptide hormone that stimulates adenylate cyclase in pituitary cells. It has now been discovered that inhibitors of PACAP receptor activity can be used for treating pelvic floor pain syndrome and overactive bladder. These receptors are membrane-bound proteins existing in various tissues. Since significant differences in functions of PACAP receptors are not observed among animal species, PACAP receptors can be used regardless of their origin. Disorders such as urinary bladder inflammation and chronic cystitis increase PACAP immunoreactivity in micturition pathways. Inhibiting PACAP may be useful in the treatment of these diseases as well as overactive bladder and pelvic floor pain syndrome.

ADVANTAGES: The inventors have demonstrated the treatment for overactive bladder and pelvic floor pain syndrome in an animal model. There are currently no therapeutic interventions that are available for these indications. Therefore, the development of these compounds could provide an important breakthrough for this population. UVM is looking for commercial partners to further the animal testing in order to bring the inhibitors to Phase I clinical trials.

PATENT STATUS: US Patent Pending

LICENSING STATUS: Worldwide rights available

CONTACT: Todd S. Keiller, Director, Technology Transfer University of Vermont

1 Pendulum Pass
Hopkinton, MA 01748

tel (508) 497-2497
fax (508) 497-0733
Todd.Keiller@uvm.edu